Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Rare Diseases

Syndrome

Preleukemia

Myelodysplastic Syndromes

Bone Marrow Diseases

Hematologic Diseases

Precancerous Conditions

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Cytarabine

Clofarabine

Antimetabolites

Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.

Clofarabine plus low dose Ara-C

Felicetto Ferrara, MD

This is an interventional, multicenter, open label, phase II study designed to evaluate the safety and efficacy of Clofarabine in combination with low dose Cytarabine in untreated patients with poor risk of Myelodisplastic Syndromes.

Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes

Phase II Study of Clofarabine in Combination With Low Dose Cytarabine for Untreated Patients With Poor Risk Myelodysplastic Syndromes

Fondazione Italiana Sindromi Mielodisplastiche-ETS

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes	NCT01302106	Myelodysplastic...	Clofarabine plu...	55 Years - 80 Years	Fondazione Italiana Sindromi Mielodisplastiche-ETS
Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes	NCT01302106	Myelodysplastic...	Clofarabine plu...	55 Years - 80 Years	Fondazione Italiana Sindromi Mielodisplastiche-ETS

Spots Global Cancer Trial Database for poor risk mds